COL18A1 and glioblastoma: Here, we studied two angiogenic inhibitors targeting different angiogenic pathways, endostatin (ES) and tumstatin (Tum), and evaluated the anti-tumorigenic activity of the individual factors and a combination of both factors in an in vivo model of GBM.